Pharmacological targets for pulmonary vascular disease: Vasodilation versus anti-remodelling

Advances in Experimental Medicine and Biology

Volumn 661, Issue , 2010, Pages 475-490

  Thomas, Matthew ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Pulmonary arterial hypertension; Remodelling; Therapy

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CHEMOKINE RECEPTOR CX3CR1; DICHLOROACETIC ACID; FASUDIL; FENCLONINE; FRACTALKINE; IMATINIB; INTERLEUKIN 6; NOTCH3 RECEPTOR; PLATELET DERIVED GROWTH FACTOR; POTASSIUM CHANNEL; POTASSIUM CHANNEL KV1.5; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SB 525334; SEROTONIN; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; VASODILATOR AGENT; NOTCH RECEPTOR; PROTEIN SERINE THREONINE KINASE; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ARTERY MUSCLE; ARTERY TONE; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; DRUG MECHANISM; DRUG TARGETING; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; VASODILATATION; ANIMAL; DISEASE COURSE; DRUG EFFECT; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; DISEASE PROGRESSION; HUMANS; HYPERTENSION, PULMONARY; PLATELET-DERIVED GROWTH FACTOR; POTASSIUM CHANNELS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, NOTCH; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SEROTONIN; VASODILATION; VENTRICULAR REMODELING;

EID: 77951213705     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60761-500-2_31     Document Type: Conference Paper

References (62)

1. Colson P, Saussine M, Séguin JR, Cuchet D, Chaptal PA, Roquefeuil B (1992) Hemodynamic effects of anesthesia in patients chronically treated with angiotensin-converting enzyme inhibitors. Anesth Analg 74:805-808
2. Narine L, Hague LK, Walker JH et al (2005) Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension. Curr Med Res Opin 21:2007-2016 (Pubitemid 41803112)
3. Kenyon KW, Nappi JM (2003) Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother 37:1055-1062 (Pubitemid 36875240)
4. Gilbert C, Brown MCJ, Cappelleri JC, Carlsson M, McKenna SP (2009) Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 135:137-142
5. Teichert-Kuliszewska K, Kutryk MJB, Kuliszewski MA et al (2006) Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for lossof- function mutations in the pathogenesis of pulmonary hypertension. Circ Res 98:209-217
6. Yang J, Davies RJ, Southwood M et al (2008) Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ Res 102:1212-1221
7. Bonnet S, Rochefort G, Sutendra G et al (2007) The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 104:11418-11423 (Pubitemid 47175155)
8. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M (2005) Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112:423-431 (Pubitemid 41022085)
9. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF (2005) Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 19:1178-1180 (Pubitemid 40946457)
10. Arciniegas E, Frid MG, Douglas IS, Stenmark KR (2007) Perspectives on endothelial-tomesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 293:L1-L8 (Pubitemid 47080705)
11. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316 (Pubitemid 29473317)
12. Balasubramaniam V, Le Cras TD, Ivy DD, Grover TR, Kinsella JP, Abman SH (2003) Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284:L826-L833 (Pubitemid 36459029)
13. Perros F, Montani D, Dorfmuller P et al (2008) Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178:81-88 (Pubitemid 351919196)
14. Schermuly RT, Dony E, Ghofrani HA et al (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811-2821 (Pubitemid 41434408)
15. Barst RJ (2005) PDGF signaling in pulmonary arterial hypertension. J Clin Invest 115:2691-2694 (Pubitemid 41434394)
16. Wang S, Wilkes MC, Leof EB, Hirschberg R (2005) Imatinib mesylate blocks a non-Smad TGF-b pathway and reduces renal fibrogenesis in vivo. FASEB J 19:1-11 (Pubitemid 40069914)
17. Nagaoka T, Fagan KA, Gebb SA et al (2005) Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171:494-499 (Pubitemid 40444250)
18. Kataoka C, Egashira K, Ishibashi M et al (2004) Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. Am J Physiol Heart Circ Physiol 286:H768-H774 (Pubitemid 38140360)
19. Watts KL, Spiteri MA (2004) Connective tissue growth factor expression and induction by transforming growth factor-b is abrogated by simvastatin via a Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 287:L1323-L1332 (Pubitemid 39507212)
20. Jiang BHM, Tawara SM, Abe KM, Takaki AP, Fukumoto YM, Shimokawa HM (2007) Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 49:85-89
21. Oka M, Fagan KA, Jones PL, McMurtry IF (2008) Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 155:444-454
22. Chapados R, Abe K, Ihida-Stansbury K et al (2006) ROK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling. Circ Res 99:837-844 (Pubitemid 44556382)
23. Tawara SM, Fukumoto YM, Shimokawa HM (2007) Effects of combined therapy with a Rhokinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 50:195-200
24. Kao PN (2005) Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 127:1446-1452 (Pubitemid 46224314)
25. Frid MG, Brunetti JA, Burke DL et al (2006) Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 168:659-669 (Pubitemid 43271163)
26. Gillespie MN, Goldblum SE, Cohen DA, McClain CJ (1988) Interleukin 1 bioactivity in the lungs of rats with monocrotaline-induced pulmonary hypertension. Proc Soc Exp Biol Med 187:26-32 (Pubitemid 18057927)
27. Perkett EA, Lyons RM, Moses HL, Brigham KL, Meyrick B (1990) Transforming growth factor-b activity in sheep lung lymph during the development of pulmonary hypertension. J Clin Invest 86:1459-1464 (Pubitemid 20372591)
28. Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144:275-285 (Pubitemid 24165948)
29. Dorfmuller P, Perros F, Balabanian K, Humbert M (2003) Inflammation in pulmonary arterial hypertension. Eur Respir J 22:358-363 (Pubitemid 36987011)
30. Balabanian K, Foussat A, Dorfmuller P et al (2002) CX3C Chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165:1419-1425 (Pubitemid 34522947)
31. Daley E, Emson C, Guignabert C et al (2008) Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 205:361-372 (Pubitemid 351281602)
32. Ulrich S, Nicolls MR, Taraseviciene L, Speich R, Voelkel N (2008) Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration 75:272-280 (Pubitemid 351450398)
33. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D et al (2007) Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 175:1280-1289 (Pubitemid 46905754)
34. Zhang TT, Okkenhaug K, Nashed BF et al (2008) Genetic or pharmaceutical blockade of p110d phosphoinositide 3-kinase enhances IgE production. J Allergy Clin Immunol 122:811-819
35. Hagen M, Fagan K, Steudel W, Carr M, Lane K, Rodman DM, West J (2007) Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol 292:L1473-L1479 (Pubitemid 47077364)
36. Song Y, Coleman L, Shi J et al (2008) Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am J Physiol Heart Circ Physiol 295:H677-H90
37. Yuan XJ (1995) Voltage-gated K+ currents regulate resting membrane potential and [Ca2+]i in pulmonary arterial myocytes. Circ Res 77:370-378
38. Archer SL, Souil E, Dinh-Xuan AT et al (1998) Molecular identification of the role of voltagegated K+ channels, KV1.5 and KV2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 101:2319-2330 (Pubitemid 28270426)
39. Cogolludo A, Moreno L, Bosca L, Tamargo J, Perez-Vizcaino F (2003) Thromboxane A2- induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: role of protein kinase CV. Circ Res 93:656-663 (Pubitemid 37222162)
40. Shimoda LA, Sylvester JT, Sham JSK (1998) Inhibition of voltage-gated K+ current in rat intrapulmonary arterial myocytes by endothelin-1. Am J Physiol Lung Cell Mol Physiol 274:L842-L853
41. Weir EK, Reeve HL, Huang JMC, Michelakis E, Nelson DP, Hampl V, Archer SL (1996) Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 94:2216-2220 (Pubitemid 26360516)
42. Remillard CV, Tigno DD, Platoshyn O et al (2007) Function of KV1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 292:C1837-C1853 (Pubitemid 47080568)
43. Pozeg ZI, Michelakis ED, McMurtry MS et al (2003) In vivo gene transfer of the O2-sensitive potassium channel KV1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 107:2037-2044 (Pubitemid 36506080)
44. Cogolludo A, Moreno L, Lodi F, Frazziano G, Cobeno L, Tamargo J, Perez-Vizcaino F (2006) Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization. Circ Res 98:931-938
45. Ekhterae D, Platoshyn O, Zhang S, Remillard CV, Yuan JX-J (2003) Apoptosis repressor with caspase domain inhibits cardiomyocyte apoptosis by reducing K+ currents. Am J Physiol Cell Physiol 284:C1405-C1410 (Pubitemid 36583381)
46. McMurtry MS, Bonnet S, Wu X, Dyck JRB, Haromy A, Hashimoto K, Michelakis ED (2004) Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95:830-840 (Pubitemid 39390586)
47. Kaufmann P, Engelstad K, Wei Y et al (2006) Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 66:324-330 (Pubitemid 43739931)
48. Harper JA, Yuan JS, Tan JB, Visan I, Guidos CJ (2003) Notch signaling in development and disease. Clin Genet 64:461-472 (Pubitemid 37493116)
49. Domenga V, Fardoux P, Lacombe P et al (2004) Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 18:2730-2735 (Pubitemid 39507766)
50. Campos AH, Wang W, Pollman MJ, Gibbons GH (2002) Determinants of Notch-3 receptor expression and signaling in vascular smooth muscle cells: implications in cell-cycle regulation. Circ Res 91:999-1006 (Pubitemid 35416636)
51. Lilly B, Kennard S (2009) Differential gene expression in a coculture model of angiogenesis reveals modulation of select pathways and a role for Notch signaling. Physiol Genomics 36:69-78
52. Belin de Chantemele EJ, Retailleau K, Pinaud F et al (2008) Notch3 is a major regulator of vascular tone in cerebral and tail resistance arteries. Arterioscler Thromb Vasc Biol 28:2216-2224
53. Bellavia D, Checquolo S, Campese AF, Felli MP, Gulino A, Screpanti I (2008) Notch3: from subtle structural differences to functional diversity. Oncogene 27:5092-5098
54. Hervé P, Launay JM, Scrobohaci ML et al (1995) Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99:249-254
55. MacLean MR, Hervé P, Eddahibi S, Adnot S (2000). 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 131:161-168
56. Willers ED, Newman JH, Loyd JE et al (2006) Serotonin transporter polymorphisms in familial and idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 173:798-802
57. Guignabert C, Izikki M, Tu LI et al (2006) Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98:1323-1330 (Pubitemid 43948088)
58. Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533-554 (Pubitemid 34219205)
59. Eddahibi S, Guignabert C, Barlier-Mur AM et al (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113:1857-1864 (Pubitemid 43739397)
60. Morecroft I, Dempsie Y, Bader M et al (2007) Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49:232-236 (Pubitemid 46360365)
61. Kay JM, Keane PM, Suyama KL (1985) Pulmonary hypertension induced in rats by monocrotaline and chronic hypoxia is reduced by p-chlorophenylalanine. Respiration 47:48-56 (Pubitemid 15152835)
62. Pissarnitski D (2007) Advances in gamma-secretase modulation. Curr Opin Drug Discov Dev 10:392-402